CD86 and neoplasm: Representative results of the flow cytometric analysis of tumor-infiltrating CD80+ CD11c+ and CD86+ CD11c+ DCs are shown in Figure 5D. The percentages of tumor-infiltrating CD80+ CD11c+ and CD86+ CD11c+ DCs were higher in mice treated with the PEK protein vaccine plus anti-PD-L1 Ab than among those treated with the PEK protein vaccine plus PBS (18.43 ± 0.14% vs. 11.02 ± 0.44%, p = 0.002, and 9.8 ± 0.12% vs. 8.32 ± 0.09%, p < 0.001, respectively, Student’s t-test for both; Figure 5E).